Nitin Yadav
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Nitin Yadav has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Virander Singh Chauhan
International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India
5 shared publications Utkarsh Kumar
3 shared publicationsMeenakshi K. Chauhan
Delhi Pharmaceut Sci & Res Univ, Delhi Inst Pharmaceut Sci & Res, Mehrauli Badarpur Rd,Sect 3, New Delhi 110017, India
2 shared publicationsPurandhi Roopmani
2 shared publications- Swaminathan Sethuraman
Tissue Engineering & Additive Manufacturing (TEAM) Lab, Centre for Nanotechnology & Advanced Biomaterials, ABCDE Innovation Centre, School of Chemical & Biotechnology, SASTRA Deemed University, India
2 shared publications Uma Maheswari Krishnan
2 shared publications
Latest Publications
- 13 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 3693-3718
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Alzheimer's disease is a progressive neurological disorder marked by amyloid-beta aggregation, tau abnormalities, impaired neuronal signaling, and related toxicities. Aβ aggregation, while a key factor, is one of several contributors, and its role as a therapeutic target continues to be explored. Efforts to target Aβ aggregation-prone regions with structure-based inhibitors face challenges like poor bioavailability, off-target effects, and limited clinical efficacy. Strategies such as small molecules, peptide therapeutics, and immunotherapies have been explored to inhibit fibrillization, while metal chelators, β-sheet breakers, and molecular chaperones help modulate aggregation and maintain protein homeostasis. Given Alzheimer's multifaceted nature, tau-directed therapies, anti-inflammatory agents, and synaptic modulators are also under investigation. Drug delivery to the brain is constrained by the blood-brain barrier, yet advances in medicinal chemistry, molecular modeling, and rational design of drugs and delivery systems are improving therapeutic strategies. This review emphasizes Aβ aggregation mechanisms and the importance of multifunctional, targeted treatments.
- 13 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (4) , 3693-3718
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Alzheimer's disease is a progressive neurological disorder marked by amyloid-beta aggregation, tau abnormalities, impaired neuronal signaling, and related toxicities. Aβ aggregation, while a key factor, is one of several contributors, and its role as a therapeutic target continues to be explored. Efforts to target Aβ aggregation-prone regions with structure-based inhibitors face challenges like poor bioavailability, off-target effects, and limited clinical efficacy. Strategies such as small molecules, peptide therapeutics, and immunotherapies have been explored to inhibit fibrillization, while metal chelators, β-sheet breakers, and molecular chaperones help modulate aggregation and maintain protein homeostasis. Given Alzheimer's multifaceted nature, tau-directed therapies, anti-inflammatory agents, and synaptic modulators are also under investigation. Drug delivery to the brain is constrained by the blood-brain barrier, yet advances in medicinal chemistry, molecular modeling, and rational design of drugs and delivery systems are improving therapeutic strategies. This review emphasizes Aβ aggregation mechanisms and the importance of multifunctional, targeted treatments.
- 6 September 2024
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 333, 103282
Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections
- 6 September 2024
- Published by Elsevier in Advances in Colloid and Interface Science
- Vol. 333, 103282
Advancements in peptide-based antimicrobials: A possible option for emerging drug-resistant infections
- 22 February 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (9) , 12609
Correction to “Ultrashort Peptide-Based Hydrogel for the Healing of Critical Bone Defects in Rabbits”
- 22 February 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (9) , 12609
Correction to “Ultrashort Peptide-Based Hydrogel for the Healing of Critical Bone Defects in Rabbits”
- 19 November 2022
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 14 (48) , 54111-54126
Ultrashort Peptide-Based Hydrogel for the Healing of Critical Bone Defects in Rabbits
The use of hydrogels as scaffolds for three-dimensional (3D) cell growth is an active area of research in tissue engineering. Herein, we report the self-assembly of an ultrashort peptide, a tetrapeptide, Asp-Leu-IIe-IIe, the shortest peptide sequence from a highly fibrillogenic protein TDP-43, into the hydrogel. The hydrogel was mechanically strong and highly stable, with storage modulus values in MPa ranges. The hydrogel supported the proliferation and successful differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in its matrix as assessed by cell viability, calcium deposition, alkaline phosphatase (ALP) activity, and the expression of osteogenic marker gene studies. To check whether the hydrogel supports 3D growth and regeneration in in vivo conditions, a rabbit critical bone defect model was used. Micro-computed tomography (CT) and X-ray analysis demonstrated the formation of mineralized neobone in the defect areas, with significantly higher bone mineralization and relative bone densities in animals treated with the peptide hydrogel compared to nontreated and matrigel treatment groups. The ultrashort peptide-based hydrogel developed in this work holds great potential for its further development as tissue regeneration and/or engineering scaffolds.
- 19 November 2022
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 14 (48) , 54111-54126
Ultrashort Peptide-Based Hydrogel for the Healing of Critical Bone Defects in Rabbits
The use of hydrogels as scaffolds for three-dimensional (3D) cell growth is an active area of research in tissue engineering. Herein, we report the self-assembly of an ultrashort peptide, a tetrapeptide, Asp-Leu-IIe-IIe, the shortest peptide sequence from a highly fibrillogenic protein TDP-43, into the hydrogel. The hydrogel was mechanically strong and highly stable, with storage modulus values in MPa ranges. The hydrogel supported the proliferation and successful differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in its matrix as assessed by cell viability, calcium deposition, alkaline phosphatase (ALP) activity, and the expression of osteogenic marker gene studies. To check whether the hydrogel supports 3D growth and regeneration in in vivo conditions, a rabbit critical bone defect model was used. Micro-computed tomography (CT) and X-ray analysis demonstrated the formation of mineralized neobone in the defect areas, with significantly higher bone mineralization and relative bone densities in animals treated with the peptide hydrogel compared to nontreated and matrigel treatment groups. The ultrashort peptide-based hydrogel developed in this work holds great potential for its further development as tissue regeneration and/or engineering scaffolds.
- 1 November 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (26) , 2023-2035
Conformationally Restricted, Dipeptide-Based, Self-Assembled Nanoparticles for Efficient Vancomycin Delivery
Aim: Emergence of vancomycin (Van) resistance, and usage of its higher dose and short half-life are posing a serious concern. Slow and sustained release of Van using a nanodelivery system may overc... Plain language summary Currently, microbial infections have become the most prevalent threat to human health. In the past few decades, researchers have tried different strategies to deal with these...
- 1 November 2022
- Published by Taylor & Francis in Nanomedicine
- Vol. 17 (26) , 2023-2035
Conformationally Restricted, Dipeptide-Based, Self-Assembled Nanoparticles for Efficient Vancomycin Delivery
Aim: Emergence of vancomycin (Van) resistance, and usage of its higher dose and short half-life are posing a serious concern. Slow and sustained release of Van using a nanodelivery system may overc... Plain language summary Currently, microbial infections have become the most prevalent threat to human health. In the past few decades, researchers have tried different strategies to deal with these...